Drug Trial Radar · NCT01983735
Efficacy and Safety of TELMINUVO to Stage 2 Hypertension
Last checked: Nov 19, 2026Latest source record: Nov 14, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
200
Planned (sponsor's estimate)
Start
Jan 2014
Primary completion
Aug 2014
Study completion Aug 2014
Sponsor
- Lead sponsor
- Chong Kun Dang PharmaceuticalIndustry
- Sponsor type
- Industry
- First posted
- Nov 14, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of present study is to evaluate the efficacy and safety of two dose combination of Telmisartan/S-Amlodipine (80/2.5mg and 80/5mg) compared with S-Amlodipine monotherapy (2.5mg and 5mg) in patients with Stage 2 hypertension.
Conditions
- Hypertension
Interventions
TELMINUVO Tab. (80/2.5mg)Drug
* Fixed dose combination of Telmisartan 80mg and S-amlodipine 2.5mg QD 2 weeks. * With the others investigation product placebo 1 tab QD 2 weeks.
TELMINUVO Tab. (80/5mg)Drug
* Fixed dose combination of Telmisartan 80mg and S-amlodipine 5mg QD 6 weeks. * With the others investigation product placebo 1 tab QD 6 weeks.
S-amlodipine 2.5mgDrug
* S-amlodipine 2.5mg QD 2 weeks * With the others investigation product placebo 1 tab QD 2 weeks.
S-amlodipine 5mgDrug
* S-amlodipine 5mg QD 6weeks * With the others investigation product placebo 1 tab QD 6 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Sitting Systolic Blood Pressure (MSSBP)Time frame: After 8 weeks of treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The catholic university of Korea Seoul St. Mary's hospital
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.